Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesenchymal stem cells + regulatory T cells
- Development stage
- Unknown
- Lead developer
- Nanjing Drum-Tower Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
mesenchymal stem cells-Nanjing Medical University-liver cirrhosis is an investigational combination cell therapy being developed by Nanjing Medical University for the treatment of decompensated liver cirrhosis and end-stage liver disease. The therapy involves the co-administration of mesenchymal stem cells (MSCs) and regulatory T cells (Tregs) via peripheral vein infusion. MSCs provide tissue repair and regenerative support, partially through the secretion of hepatocyte growth factor (HGF), while Tregs modulate the immune environment and enhance MSC efficacy via TGF-β and indoleamine 2,3-dioxygenase (IDO) signaling. This individualized medicine approach is currently being evaluated in Phase 1/2 clinical trials to assess safety and efficacy in improving liver function and reducing injury severity.
- Other names
- MSC and Tregsmesenchymal stem cells and regulatory T cellsmesenchymal stem cells-Nanjing Medical University-liver cirrhosis
Beyond the preview
Go deeper on mesenchymal stem cells + regulatory T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesenchymal stem cells + regulatory T cells.